CD96

CD96 is an immunoglobulin superfamily receptor that functions as a context-dependent immune checkpoint on NK cells, CD8+ T cells, and CD4+ Th9 cells by engaging CD155 (PVR/necl-5) and nectin-1 through its membrane-distal first Ig-like V-domain (PMID:19056733, PMID:30528596, PMID:30759143). On NK cells, CD96 acts as an inhibitory receptor that competes with the activating receptor CD226 (DNAM-1) for CD155 binding, thereby restraining NK cell cytotoxicity and cytokine production; anti-tumor effects of CD96 blockade in metastasis models require intact CD226 signaling (PMID:24658051, PMID:29721390). On CD8+ T cells, CD96 exerts a dual role: genetic ablation enhances anti-tumor immunity in a CD226-, Batf3-, and IFNγ-dependent manner, yet crosslinking CD96 can also co-stimulate effector function via MEK-ERK signaling (PMID:30894377, PMID:32043568). Loss-of-function mutations in CD96 cause C (Opitz trigonocephaly) syndrome, a developmental disorder linked to disrupted cell adhesion mediated by the extracellular domain (PMID:17847009).

1. 2007 Medium

   CD96 was established as a cell-surface marker that distinguishes leukemic stem cells from normal hematopoietic stem cells, raising the question of whether CD96 has a functional role beyond lineage marking in hematopoietic malignancy.

   Evidence FACS sorting of CD96+ vs CD96− AML fractions followed by xenotransplantation into Rag2−/−γc−/− mice

   PMID:17576927

   Open questions at the time

   • Whether CD96 expression is functionally required for leukemic stem cell engraftment or is merely a surface marker
   • No signaling mechanism defined in AML cells
2. 2007 Medium

   Human genetic studies established that CD96 mutations cause C (Opitz trigonocephaly) syndrome, and the disease-associated T280M mutation in the third Ig domain abolished cell adhesion and growth activities, demonstrating that CD96 functions as a cell adhesion molecule during development.

   Evidence Human mutation analysis; in vitro cell adhesion and growth assays with mutant CD96

   PMID:17847009

   Open questions at the time

   • Single functional readout in vitro; no in vivo rescue or animal model confirmation
   • Developmental signaling pathway downstream of CD96 adhesion not characterized
3. 2008 High

   Domain-mapping experiments resolved that CD96 engages both CD155 and nectin-1 via its first (membrane-distal) Ig-like V-domain, with downstream Ig domains modulating binding affinity, answering the structural basis for ligand recognition and explaining how alternative splicing and the T280M mutation alter binding.

   Evidence Chimeric human/murine CD96 constructs; splice variant characterization; binding assays with domain deletions and point mutations

   PMID:19056733

   Open questions at the time

   • Three-dimensional structural basis of recognition not yet determined at this stage
   • Functional consequences of splice variant differences on immune cell activity not tested
4. 2014 High

   Using Cd96−/− mice, CD96 was definitively shown to function as an inhibitory receptor on NK cells that competes with the activating receptor CD226 for CD155 binding, establishing CD96 as an immune checkpoint that restrains NK cell anti-tumor and anti-metastatic responses.

   Evidence Cd96−/− mice challenged with LPS and experimental metastasis models; binding competition assays; NK cell functional assays

   PMID:24658051

   Open questions at the time

   • Intracellular signaling mechanism downstream of CD96 in NK cells not defined
   • Whether the inhibitory role extends to T cells not yet tested
5. 2018 High

   Structural resolution of the CD96-D1/CD155-D1 complex by X-ray crystallography revealed a conserved lock-and-key interface plus a novel 'ancillary key' motif unique to CD96, explaining how CD96 achieves specific necl-5 recognition and competes with CD226 at a molecular level.

   Evidence X-ray crystallography of CD96-D1 bound to CD155-D1; mutational validation of interface residues; binding assays

   PMID:30528596

   Open questions at the time

   • Structure of full-length CD96 ectodomain with all three Ig domains not determined
   • How the ancillary key motif affects in vivo binding dynamics not established
6. 2018 High

   Anti-CD96 monoclonal antibody mapping showed that blocking the CD96-CD155 interaction at D1 was sufficient for anti-metastatic activity, while a D2-binding non-blocking mAb also retained activity in CD155-deficient mice; all anti-CD96 efficacy required CD226, positioning CD226 as an obligate downstream effector of CD96 checkpoint blockade.

   Evidence Comparative mAb epitope mapping; experimental and spontaneous metastasis models in CD155−/−, IL-12p35−/−, and CD226−/− mice

   PMID:29721390

   Open questions at the time

   • Mechanism by which the D2-binding mAb exerts CD155-independent anti-metastatic activity is unexplained
   • Whether anti-CD96 therapy acts primarily on NK cells versus T cells in these models is unresolved
7. 2018 Medium

   CD96 was identified as an inhibitory co-signaling receptor on Th9 cells: CD96-high Th9 cells were functionally suppressed while CD96-low Th9 cells exhibited greater IL-9 production and inflammatory tissue-invasive potential, extending the checkpoint function of CD96 beyond NK cells to CD4+ T helper subsets.

   Evidence Single-cell transcription profiling; CD96high/low Th9 subset transfer into Rag1−/− mice; anti-CD96 blockade in vivo

   PMID:29531070

   Open questions at the time

   • Intracellular signaling pathway mediating CD96 inhibition of Th9 function not defined
   • Whether CD155 is the relevant ligand for CD96 on Th9 cells not directly shown
8. 2019 High

   Genetic epistasis in tumor models revealed that CD96 functions as an immune checkpoint on CD8+ T cells: Cd96−/− CD8+ T cells mediated superior tumor rejection through a pathway requiring CD226, Batf3-dependent cross-presentation, IL-12, and IFNγ, establishing the immune cell hierarchy downstream of CD96 loss.

   Evidence Cd96−/− mice crossed with Cd226−/−, Batf3−/−, and cytokine-deficient strains; multiple tumor challenge models; CD8+ T cell depletion

   PMID:30894377

   Open questions at the time

   • Direct intracellular signaling mechanism in CD8+ T cells downstream of CD96 engagement not identified
   • Whether CD96 inhibition operates cell-autonomously in CD8+ T cells versus through altered APC crosstalk
9. 2020 Medium

   CD96 crosslinking on CD8+ T cells was shown to co-stimulate activation, proliferation, and cytokine production via MEK-ERK signaling, revealing a co-stimulatory capacity that contrasts with its checkpoint-inhibitory role observed in NK cells and tumor models, and demonstrating context-dependent signaling downstream of CD96.

   Evidence Anti-CD96 crosslinking assays on human and mouse CD8+ T cells; MEK inhibitor treatment; Cd96−/− mice; flow cytometry for NUR77, T-bet, and cytokines

   PMID:32043568

   Open questions at the time

   • Apparent contradiction between co-stimulatory crosslinking data and inhibitory genetic ablation phenotype not resolved
   • Specific intracellular motif(s) in the CD96 cytoplasmic tail mediating MEK-ERK activation not mapped
10. 2022 Medium

    A tumor cell-intrinsic role for CD96 was uncovered: in breast cancer stem cells, CD96 engagement of CD155 activates a Src-Stat3-Opa1 axis that enhances mitochondrial fatty acid β-oxidation, conferring chemoresistance — expanding CD96 function beyond immune regulation to metabolic reprogramming in tumor cells.

    Evidence CD96 inhibition in patient-derived xenograft; biochemical pathway dissection of CD155-CD96-Src-Stat3-Opa1; mitochondrial FAO assays

    PMID:36581470

    Open questions at the time

    • Whether this tumor-intrinsic signaling pathway operates in non-breast cancer contexts
    • Relationship between immune checkpoint function and tumor-intrinsic CD96 signaling not integrated
11. 2023 Medium

    The CD155-CD96 axis was placed upstream of pathogenic Th9 differentiation in giant cell arteritis: macrophages that retain CD155 intracellularly fail to engage CD96 on CD4+ T cells, leading to unchecked IL-9-producing Th9 expansion and vascular inflammation, providing a disease mechanism linking CD96 ligand availability to autoimmune vasculitis.

    Evidence Patient-derived macrophage analysis; humanized mouse model of GCA; recombinant IL-9 and anti-IL-9 antibody intervention

    PMID:37075705

    Open questions at the time

    • Mechanism by which macrophages retain CD155 in the ER not defined
    • Whether therapeutic targeting of CD96 itself would ameliorate GCA not tested

• The molecular basis for CD96's context-dependent switching between inhibitory and co-stimulatory signaling remains unresolved: the cytoplasmic domain motifs responsible for each output, and whether specific ligand-binding geometries or co-receptor interactions determine signaling polarity, are key open questions.
• Cytoplasmic tail signaling motifs and adaptor proteins mediating inhibitory versus co-stimulatory outputs not mapped
• Full-length ectodomain structure including modulation by Ig domains D2/D3 not solved
• No integrative model reconciling NK cell inhibition, CD8+ T cell co-stimulation, and tumor-intrinsic metabolic signaling